October 13, 2011—The Department of Health and Human Services Office of Inspector General (OIG) plans to take a second look this coming year at drug manufacturers' reporting of their average manufacturer prices (AMPs) after concluding last year that more than half had recently missed at least one quarterly reporting deadline. OIG also says in its fiscal year 2012 work plan … [Read more...]
Whistleblower Says 13 Drug Firms Understate Average Manufacturer Prices
Wholesaler fees allegedly misreported to reduce Medicaid rebate obligations.October 6, 2011—A whistleblower who once led the trade association for drug wholesalers and health care product distributors has accused 13 brand-name drug manufacturers in a federal lawsuit of artificially lowering their drugs' average manufacturer prices (AMPs) by misreporting fees they pay to wholesalers. The lawsuit, which was filed under seal three years ago and made … [Read more...]
340B Provider Groups Protest Two PBMs’ Reimbursement Policies
Prescription Solutions and Argus Health Systems contracts come under fire."Providers, manufacturers, and Congress should be concerned about these discriminatory contracts because they undermine the intent of Congress to support safety net providers through the 340B program," says CaptureRx executive and former U.S. Rep. Billy Tauzin October 6, 2011—Groups representing 340B providers have asked pharmacy benefits manager (PBM) Prescription … [Read more...]
House’s Draft HHS Appropriation Would Cut OPA Funding in Half
340B office's spending would drop from $4.48 billion to $2.21 billion, with no mention of user fee.September 29, 2011—The full House Appropriations Committee today released a draft fiscal 2012 funding bill for the Department of Health and Human Services (HHS) that would cut funding for the Office of Pharmacy Affairs (OPA) by roughly 50 percent, from $4.48 million to $2.21 million. The draft bill and accompanying documents also appear not to mention the 0.1 percent user … [Read more...]
Court Ruling Might Put Some Hospitals’ 340B Status in Jeopardy
Dispute over where Medicare managed care belongs in the DSH calculation.September 27, 2011—A recent federal appeals court ruling on how Medicare managed care beneficiaries should be factored into a hospital's Medicare disproportionate share (DSH) patient percentage could potentially lead to hospitals being terminated from the 340B drug discount program—particularly in states with high Medicare managed care utilization. In Northeast Hospital … [Read more...]
GOP Leaders Ask HRSA for Details on 340B Oversight
Request comes as GAO releases a major report on the program.September 23, 2011—Three influential Republican members of Congress asked the Health Resources and Services Administration (HRSA) yesterday for a detailed accounting of its oversight of the 340B drug discount program. Their Sept. 22 letter to HRSA Administrator Mary Wakefield came to light this morning just hours before the Government Accountability Office (GAO) released a … [Read more...]
Senate Appropriations Committee Weighs in on 340B Program
Approves user fee and urges HRSA to address providers' concerns.September 23, 2011—The Senate Appropriations Committee has approved a fiscal 2012 spending bill for the departments of Labor, Health and Human Services, and Education that includes a number of provisions affecting 340B stakeholders. As first reported in Monitor earlier this week, the committee has approved the first-ever user fee for providers enrolled in 340B. The 0.1 … [Read more...]